VistaGen Therapeutics Inc. (VTGN) is priced at $2.79 after the most recent trading session. At the very opening of the session, the stock price was $2.80 and reached a high price of $2.855, prior to closing the session it reached the value of $2.77. The stock touched a low price of $2.73.
Recently in News on June 16, 2021, VistaGen Therapeutics Set to Join the Russell 2000® Index. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the Company will be added to the Russell 2000® Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opens on Monday, June 28, 2021, according to a preliminary list of additions posted on June 4, 2021. You can read further details here
VistaGen Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.18 on 02/22/21, with the lowest value was $1.83 for the same time period, recorded on 02/10/21.
VistaGen Therapeutics Inc. (VTGN) full year performance was 451.38%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, VistaGen Therapeutics Inc. shares are logging -12.26% during the 52-week period from high price, and 506.52% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.46 and $3.18.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2460438 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the VistaGen Therapeutics Inc. (VTGN) recorded performance in the market was 43.81%, having the revenues showcasing 21.30% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 400.95M, as it employees total of 9 workers.
Specialists analysis on VistaGen Therapeutics Inc. (VTGN)
During the last month, 0 analysts gave the VistaGen Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.32, with a change in the price was noted +0.58. In a similar fashion, VistaGen Therapeutics Inc. posted a movement of +26.24% for the period of last 100 days, recording 3,126,423 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for VTGN is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: VistaGen Therapeutics Inc. (VTGN)
Raw Stochastic average of VistaGen Therapeutics Inc. in the period of last 50 days is set at 73.95%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 64.77%. In the last 20 days, the company’s Stochastic %K was 65.84% and its Stochastic %D was recorded 68.39%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 43.81%. Additionally, trading for the stock in the period of the last six months notably improved by 273.34%, alongside a boost of 451.38% for the period of the last 12 months. The shares increased approximately by -0.36% in the 7-day charts and went down by 24.00% in the period of the last 30 days. Common stock shares were driven by 21.30% during last recorded quarter.